Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents
<p>Abstract</p> <p>Background</p> <p>Disease specific mortality is often used as outcome rather than total mortality in clinical trials. This approach assumes that the classification of cause of death is unbiased. We explored whether use of fungal infection-related mort...
Main Authors: | Gøtzsche Peter C, Johansen Helle K, Due Anne K |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-08-01
|
Series: | BMC Medical Research Methodology |
Online Access: | http://www.biomedcentral.com/1471-2288/6/40 |
Similar Items
-
Fungal Spectrum and Susceptibility Against Nine Antifungal Agents in 525 Deep Fungal Infected Cases
by: Cai W, et al.
Published: (2023-07-01) -
PC945, a Novel Inhaled Antifungal Agent, for the Treatment of Respiratory Fungal Infections
by: Alison Murray, et al.
Published: (2020-12-01) -
Cholesterol and total mortality: need for larger trials.
by: Collins, R, et al.
Published: (1992) -
Fungal infections: Pathogenesis, antifungals and alternate treatment approaches
by: G.Kiran Kumar Reddy, et al.
Published: (2022-01-01) -
Cancer incidence and mortality in the Norwegian Fire Departments cohort: Are incidence versus mortality outcome measures contributing to variability in risk estimates?
by: Niki Marjerrison, et al.
Published: (2022-01-01)